Protalix BioTherapeutics, Inc. PLX R2K

Healthcare · Biotechnology · United States

https://www.protalix.com

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Market & Price

Market Cap

$170.01M

Current Price

$2.11

High / Low (52W)

$3.15 / $1.35

Beta

-0.01

Valuation

Stock P/E

11.11

Industry PE

23.65

Forward P/E

3.40

PEG Ratio

Book Value

$0.83

Price to Book

2.53

P/S

2.23

EV/EBITDA

5.98

Dividend Yield

Profitability & Returns

ROCE

-7.91%

ROE

27.27%

ROA

14.04%

Profit Margin

20.07%

Op Margin

62.65%

EPS (Latest Qtr)

$0.22

EPS (TTM)

$0.19

Balance Sheet & Liquidity

Debt/Equity

0.13

Quick Ratio

1.97

Current Ratio

3.15

Debt

$8.48M

Total Assets

$82.35M

Current Assets

$66.67M

Working Capital

$40.16M

Ownership

Promoter Holding

3.88%

Chg in Prom Hold

FII / Inst Holding

21.30%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$127.40M

Total Revenue (TTM)

$76.38M

EBITDA

$21.31M

Free Cash Flow

$6.78M

Operating Cash Flow

$15.09M

Shares Outstanding

80.57M

Gross Margin

45.24%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

3.45%

Profit 5Y

18.59%

Revenue (YoY)

233.70%

Earnings (YoY)

PROS

Strong return on equity of 27.3%.
Excellent profit margin of 20.1%.
Profit CAGR of 18.6% over 5 years.
Generates positive free cash flow.

CONS

Trading 33.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PLX Protalix BioTherapeutics, Inc. R2K	2.11	11.11	$170.01M	-	-7.91%	27.27%	3.45%	18.59%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	6.70M	2.42M	2.40M	1.69M	1.34M	1.34M	679.00K	1.77M	4.67M	2.89M	6.36M	7.53M	4.55M	2.01M	663.00K	-	10.44M	12.25M	14.25M	-	21.65M	10.97M	10.79M	11.32M	6.43M	12.05M	16.09M	8.75M	14.18M	9.59M	35.08M	10.35M	3.75M	13.47M	-	10.11M	15.66M	17.85M	9.12M	33.75M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.18M	5.87M	8.32M	4.62M	4.13M
Gross Profit	3.31M	1.08M	1.91M	1.41M	1.11M	1.11M	156.00K	94.00K	422.00K	801.00K	835.00K	1.46M	1.63M	-177.00K	-1.25M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.93M	9.79M	9.53M	4.50M	29.62M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.08M	8.62M	7.40M	9.16M	8.48M
Operating Income	-6.47M	-5.45M	-6.21M	-5.38M	-5.58M	-5.00M	-7.86M	-9.93M	-6.65M	-6.37M	-10.80M	-7.76M	-5.15M	-6.74M	-3.74M	-3.67M	-5.53M	-5.84M	-1.54M	2.20M	4.69M	-2.24M	-2.58M	-3.71M	-9.17M	-1.89M	-1.87M	-5.52M	-3.12M	-2.46M	20.42M	-1.89M	-4.86M	-2.43M	-	-4.14M	1.17M	2.13M	-4.66M	21.15M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.38M	1.80M	2.79M	-4.01M	21.74M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00K	783.00K	180.00K	383.00K	193.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.73M	661.00K	2.24M	-4.78M	21.14M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-113.00K	497.00K	-116.00K	728.00K	2.82M
Net Income	-7.34M	-6.12M	-8.01M	-5.97M	-5.07M	-3.82M	-8.60M	-10.85M	-7.29M	-59.15M	450.00K	-11.44M	-7.24M	-8.46M	-5.32M	-5.43M	-7.26M	-7.74M	-3.56M	291.00K	1.67M	-4.15M	-4.44M	-5.47M	-11.24M	-4.20M	-2.29M	-5.33M	-3.57M	-3.13M	19.34M	-1.85M	-4.59M	-2.20M	-	-3.62M	164.00K	2.35M	-5.50M	18.32M
Diluted EPS	-	-	-	-	-	-	-	-0.11	-	-	-0.06	-	-	-0.06	-	-	-	-	-	-	-	-	-0.14	-0.14	-0.25	-0.09	-0.05	-0.11	-0.07	-0.05	0.21	-0.04	-0.06	-0.03	0.03	-0.05	0.00	0.03	-	0.22
R&D Expense	8.15M	7.08M	8.05M	6.10M	6.02M	5.07M	7.33M	10.01M	6.35M	5.97M	9.30M	7.12M	7.29M	7.48M	10.07M	-	11.70M	13.32M	10.00M	-	10.34M	9.19M	7.69M	7.12M	7.69M	7.28M	8.77M	7.58M	7.39M	5.85M	4.47M	3.67M	2.89M	2.96M	3.00M	3.48M	5.99M	4.47M	-	5.43M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	388.00K	6.64M	8.39M	34.87M	0	3.52M	4.36M	9.20M	21.08M	34.24M	54.69M	62.90M	38.35M	47.64M	65.49M	53.40M	52.74M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	19.59M	22.98M	24.32M	26.99M
Gross Profit	-3.19M	6.86M	1.44M	26.28M	0	2.89M	3.63M	801.00K	4.01M	-	-	-	-	28.05M	42.51M	29.08M	25.75M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	41.06M	32.05M	25.16M	31.25M
Operating Income	-31.97M	-29.97M	-36.53M	-12.17M	-34.06M	-28.56M	-23.67M	-33.16M	-34.52M	-19.31M	-10.72M	2.71M	-20.46M	-13.01M	10.46M	3.92M	-5.50M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-10.78M	12.94M	6.52M	-2.95M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	2.53M	3.18M	1.06M	1.19M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-14.40M	8.57M	4.15M	-5.61M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	530.00K	254.00K	1.22M	996.00K
Net Income	-31.44M	-29.00M	-36.53M	-11.62M	-27.79M	-29.94M	58.04M	-29.36M	-83.44M	-26.46M	-18.28M	-6.52M	-27.58M	-14.93M	8.31M	2.93M	-6.60M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-1.23	-0.22	-0.62	-0.31	0.09	0.04	-0.08
R&D Expense	27.39M	37.69M	37.82M	36.66M	29.23M	27.35M	24.89M	30.41M	32.17M	33.33M	44.62M	38.17M	29.73M	29.35M	17.09M	12.97M	19.57M

Compounded Sales Growth

5 Years:	3.45%
1 Year:	233.70%

Compounded Profit Growth

5 Years:	18.59%
1 Year:	-

Stock Price Performance

1 Year:	+36.13%
6 Months:	+17.88%
3 Months:	-26.74%
1 Month:	-0.47%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	64.73M	51.80M	78.73M	113.33M	78.36M	97.25M	82.25M	72.21M	61.13M	45.39M	67.93M	-	55.79M	84.43M	73.42M	82.35M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44.88M	69.93M	60.08M	66.67M
Cash & Equivalents	42.60M	81.27M	35.90M	27.00M	52.03M	86.40M	54.77M	76.37M	63.28M	51.16M	37.81M	17.79M	18.27M	-	17.11M	23.63M	19.76M	14.68M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.80M	19.05M	21.24M	25.73M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.59M	5.27M	2.91M	8.84M
Total Liabilities	-	-	76.05M	77.88M	82.08M	140.28M	133.96M	86.38M	92.20M	101.67M	114.01M	115.71M	94.97M	-	66.43M	50.87M	30.21M	34.12M
Current Liabilities	-	-	18.90M	18.69M	25.75M	26.70M	64.35M	11.23M	66.21M	22.75M	25.35M	40.17M	86.47M	-	32.43M	45.53M	25.62M	26.52M
Long Term Debt	-	-	-	6.57M	5.42M	2.37M	912.00K	-	-	-	-	-	-	27.89M	28.19M	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33.47M	26.28M	5.53M	8.32M
Total Equity	44.35M	15.88M	-11.32M	-26.08M	-3.36M	-26.95M	-55.60M	10.87M	-9.96M	-29.46M	-52.88M	-70.32M	-27.04M	-	-10.64M	33.57M	43.21M	48.23M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53.79M	72.95M	75.85M	80.43M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	44.45M	-38.46M	-23.57M	635.00K	-30.65M	-29.28M	-24.28M	-32.10M	-9.99M	-7.74M	-19.36M	-26.11M	-	-25.00M	-1.32M	8.67M	-11.99M
Investing Cash Flow	-6.17M	-7.99M	-5.87M	-2.29M	-2.10M	-1.00M	39.39M	-967.00K	-1.12M	-591.00K	-883.00K	-19.95M	-	-5.04M	-16.71M	4.22M	-2.37M
Financing Cash Flow	293.00K	501.00K	20.93M	26.56M	-	-	6.63M	19.70M	-1.42M	-4.75M	0	46.47M	-	8.24M	24.67M	-16.79M	9.33M
Capital Expenditure	-6.20M	-7.86M	-5.71M	-2.07M	-1.89M	-785.00K	-464.00K	-849.00K	-971.00K	-686.00K	-627.00K	-655.00K	-	-628.00K	-1.15M	-1.28M	-1.64M
Free Cash Flow	38.26M	-46.32M	-29.27M	-1.43M	-32.54M	-30.07M	-24.75M	-32.95M	-10.96M	-8.43M	-19.98M	-26.76M	-	-25.63M	-2.47M	7.39M	-13.63M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-21.80M	6.64M	-3.90M	-5.03M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-821.4%	103.3%	17.2%	75.4%	-	82.1%	83.3%	8.7%	19.0%	-	-	-	-	58.9%	64.9%	54.5%	48.8%
Operating Margin %	-8,239.4%	-451.2%	-435.6%	-34.9%	-	-810.6%	-542.4%	-360.5%	-163.8%	-56.4%	-19.6%	4.3%	-53.4%	-27.3%	16.0%	7.3%	-10.4%
Net Margin %	-8,103.1%	-436.6%	-435.6%	-33.3%	-	-849.9%	1,329.9%	-319.2%	-395.9%	-77.3%	-33.4%	-10.4%	-71.9%	-31.3%	12.7%	5.5%	-12.5%
ROE %	-197.9%	256.1%	140.1%	346.1%	103.1%	53.9%	533.8%	294.9%	283.3%	50.0%	26.0%	24.1%	-	140.3%	24.8%	6.8%	-13.7%
ROCE %	-	-65.4%	-110.3%	-23.0%	-39.3%	-203.9%	-27.5%	-206.8%	-69.8%	-54.0%	-205.4%	-14.6%	-	-55.7%	26.9%	8.2%	-9.9%

Shareholding Pattern

Insiders

3.88%

Institutions

21.30%

Public Float

22.16%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	4.49%	3.62M	$7.63M
2	MAK Capital One LLC	4.40%	3.54M	$7.48M
3	Renaissance Technologies, LLC	1.52%	1.22M	$2.58M
4	State Street Corporation	1.21%	972.82K	$2.05M
5	Northern Trust Corporation	1.10%	885.45K	$1.87M
6	Geode Capital Management, LLC	1.07%	865.30K	$1.83M
7	Stratos Wealth Partners, Ltd.	0.62%	500.00K	$1.05M
8	Vanguard Portfolio Management LLC	0.54%	432.49K	$912.54K
9	Prospera Financial Services Inc.	0.52%	418.57K	$883.18K
10	Opaleye Management Inc.	0.42%	340.00K	$717.40K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PLX

No recent headlines available.

PLX · Healthcare